News Column

Studies in the Area of Therapeutics and Clinical Risk Management Reported from Case Western Reserve University (Clinical and economic studies of...

September 12, 2014



Studies in the Area of Therapeutics and Clinical Risk Management Reported from Case Western Reserve University (Clinical and economic studies of eptifibatide in coronary stenting)

By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Health and Medicine. According to news reporting originating from Cleveland, Ohio, by NewsRx correspondents, research stated, "Platelet adhesion and aggregation at the site of coronary stenting can have catastrophic clinical and economic consequences. Therefore, effective platelet inhibition is vital during and after percutaneous coronary intervention."

Our news editors obtained a quote from the research from Case Western Reserve University, "Eptifibatide is an intravenous antiplatelet agent that blocks the final common pathway of platelet aggregation and thrombus formation by binding to glycoprotein IIb/IIIa receptors on the surface of platelets. In clinical studies, eptifibatide was associated with a significant reduction of mortality, myocardial infarction, or target vessel revascularization in patients with acute coronary syndrome undergoing percutaneous coronary intervention. However, recent trials conducted in the era of dual antiplatelet therapy and newer anticoagulants failed to demonstrate similar results. The previously seen favorable benefit of eptifibatide was mainly offset by the increased risk of bleeding. Current American College of Cardiology/American Heart Association guidelines recommend its use as an adjunct in high-risk patients who are undergoing percutaneous coronary intervention with traditional anticoagulants (heparin or enoxaparin), who are not otherwise at high risk of bleeding. In patients receiving bivalirudin (a newer safer anticoagulant), routine use of eptifibatide is discouraged except in select situations (eg, angiographic complications). Although older pharmacoeconomic studies favor eptifibatide, in the current era of P2Y(12) inhibitors and newer safer anticoagulants, the increased costs associated with bleeding make the routine use of eptifibatide an economically nonviable option. The cost-effectiveness of eptifibatide with the use of strategies that decrease the bleeding risk (eg, transradial access) is unknown."

According to the news editors, the research concluded: "This review provides an overview of key clinical and economic studies of eptifibatide well into the current era of potent antiplatelet agents, novel safer anticoagulants, and contemporary percutaneous coronary intervention."

For more information on this research see: Clinical and economic studies of eptifibatide in coronary stenting. Therapeutics and Clinical Risk Management, 2014;10():603-614. Therapeutics and Clinical Risk Management can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Health and Medicine).

The news editors report that additional information may be obtained by contacting T. Pasala, Case Western Reserve University, MetroHealth, Heart & Vasc Center, Cleveland, OH 44109, United States. Additional authors for this research include P. Sattayaprasert, P.K. Bhat, G. Athappan and S. Gandhi.

Keywords for this news article include: Cleveland, Ohio, United States, North and Central America, Health and Medicine

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters